This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A phase 1b/2 study with the agonistic TRAIL-R1 ant...
Clinical trial

A phase 1b/2 study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with cisplatin and radiotherapy as a first line therapy in patients with advanced cervical cancer

Read time: 1 mins
Last updated:23rd Sep 2009
Phase 1b: To evaluate the safety and tolerability of escalating doses of mapatumumab in combination with cisplatin and radiotherapy in subjects with locally advanced cervical cancer. Phase 2: To evaluate the efficacy of mapatumumab in combination with cisplatin and radiotherapy in subjects with locally advanced cervical cancer.
Category Value
Study start date 2009-09-23

View full details